Fatty liver and chronic inflammation in Chinese adults

Diabetes Research and Clinical Practice

Volumn 81, Issue 2, 2008, Pages 202-208

  Wang, Pei Wen ^a   Hsieh, Ching Jung ^a   Psang, Leung Chit ^a   Cheng, Yu Fan ^a   Liou, Chia Wei ^a   Weng, Shao Wen ^a   Chen, Jung Fu ^a   Chen, I Ya ^a   Li, Rong Hwai ^a   Eng, Hock Liew ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Adiponectin; C reactive protein; Fatty liver; Insulin resistance; Metabolic syndrome

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHINESE; CHRONIC INFLAMMATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FATTY LIVER; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIVER; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; REGRESSION ANALYSIS; SPLEEN;

ADIPONECTIN; ADULT; CHINA; CYTOKINES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; PATIENT SELECTION; PREVALENCE; TAIWAN;

EID: 47649119315     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.04.014     Document Type: Article

References (62)

1. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
2. Haffner S.M., Valdez R.A., Hazuda H.P., Mitchell B.D., Morales P.A., and Stern M.P. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41 (1992) 715-722
3. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab. Care 24 (2001) 683-689
4. Trevisan M., Liu J., Bahsas F.B., and Menotti A. Syndrome X and mortality: a population-based study. Am. J. Epidemiol. 148 (1998) 958-966
5. Kelly D.E., and Goodpaster B.H. Skeletal muscle triglyceride. Diab. Care 24 (2001) 933-941
6. Seppälä-Lindroos A., Vehkavaara S., Häkkinen A.M., Goto T., Westerbacka J., Sovijärvi A., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87 (2002) 3023-3028
7. Ravussin E., and Smith S.R. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann. NY Acad. Sci. 967 (2002) 363-378
8. Bays H., Mandarino L., and DeFronzo R.A. Role of adipocyte, free fatty acid, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 89 (2004) 463-478
9. Goodpaster B.H., He J., Watkins S., and Kelly D.E. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab. 86 (2001) 5755-5761
10. Puder J.J., Varga S., Kraenzlin M., De Geyter C., Keller U., and Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J. Clin. Endocrinol. Metab. 90 (2005) 6014-6021
11. Petersen K.F., Oral E.A., Dufour S., Befroy D., Ariyan C., Yu C., et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109 (2002) 1345-1350
12. Lee J.H., Chan J.L., Sourlas E., Raptopoulos V., and Mantzoros C.S. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 91 (2006) 2605-2611
13. Kim J.K., Gavrilova O., Chen Y., Reitman M.L., and Shulman G.I. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J. Biol. Chem. 275 (2000) 8456-8460
14. Petersen K.F., Dufour S., Befroy D., Garcia R., and Shulman G.I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 350 (2004) 664-671
15. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
16. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
17. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with insulin resistance syndrome. Hepatology 35 (2002) 373-379
18. Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35 (2002) 367-372
19. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
20. Pittas A.G., Joseph N.A., and Greenberg A.S. Adipocytokines and insulin resistance I. Clin. Endocrinol. Metab. 89 (2004) 447-452
21. Wellen K.E., and Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 115 (2005) 1111-1119
22. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakujima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114 (2004) 1752-1761
23. Shoelson S.E., Lee J., and Goldfine A.B. Inflammation and insulin resistance. J. Clin. Invest. 116 (2006) 1793-1801
24. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J. Clin. Invest. 106 (2000) 473-481
25. Dandona P., Aljada A., Chaudhuri A., Mohanty P., and Garg R. Metabolic syndrome. A comprehensive perspective based on interaction between obesity, diabetes, and inflammation. Circulation 111 (2005) 1448-1454
26. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 285 (2001) 2486-2497.
27. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., and Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
28. Gill T.P. Cardiovascular risk in the Asia-Pacific region from a nutrition and metabolic point of view: abdominal obesity. Asia Pac. J. Clin. Nutr. 10 (2001) 85-89
29. World Health Organization, The Asia-Pacific Perspective: Redefining Obesity and its Treatment, WHO, Geneva, 2000.
30. Tan C.E., Ma S., Wai D., Chew S.K., and Tai E.S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diab. Care 27 (2004) 1182-1186
31. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28 (1985) 412-419
32. Cheng Y.F., Chen C.L., Lai C.Y., Chen T.Y., Huang T.L., Lee T.Y., et al. Assessment of donor fatty livers for liver transplantation. Transplantation 71 (2001) 1221-1225
33. Meigs J.B. The metabolic syndrome. BMJ 327 (2003) 61-62
34. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diab. Care 28 (2005) 2289-2304
35. Kim S.H., and Reaven G.M. The metabolic syndrome: one step forward, two steps back. Diab. Vasc. Dis. Res. 1 (2004) 68-75
36. Reilly M.P., and Rader D.J. The metabolic syndrome: more than the sum of its parts?. Circulation 108 (2003) 1546-1551
37. Malik S., Wong N.D., Franklin S.S., Kamath T.V., L'Italian G.J., Pio J.R., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (2004) 1245-1250
38. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diab. Care 28 (2005) 1769-1778
39. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland Coronary Prevention Study. Circulation 108 (2003) 141-419
40. Fan J.G., Zhu J., Li X.J., Chen L., Lu Y.S., Li L., et al. Fatty liver and the metabolic syndrome among Shanghai adults. J. Gastroenterol. Hepatol. 20 (2005) 1825-1832
41. Vozarova B., Stefan N., Lindsay R.S., Saremi A., Pratley R.E., Bogardus C., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51 (2002) 1889-1895
42. Lee D.S., Evans J.C., Robins S.J., Wilson P.W., Albano I., Fox C.S., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 127-133
43. Haffner S.M. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity 14 Suppl. 3 (2006) 121S-127S
44. Cheal K.L., Abbasi F., Lamendola C., McLaughlin T., Reaven G.M., and Ford E.S. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53 (2004) 1195-1200
45. ToledoFG, Sniderman A.D., and Kelly D.E. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diab. Care 29 (2006) 1845-1850
46. Kelly D.E., McKolanis T.M., Hegazi R.A., Kuller L.H., and Kalhan S.C. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 285 (2003) E906-E916
47. Bugianesi E., Pagotto U., Manini R., Vanni E., Gastaldelli A., Iasio R., et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab. 90 (2005) 3498-3504
48. Yoneda M., Iwasaki T., Fujita K., Kirikoshi H., Inamori M., Nozaki Y., et al. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue. Alcohol. Clin. Exp. Res. 31 (2007) 15S-21S
49. Wong V.W.-S., Hui A.Y., Tsang S.W.-C., Chan J.L.-Y., Tse A.M.-L., Chan K.F., et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 4 (2006) 1154-1161
50. Mendez-Sanchez N., Chavez-Tapia N.C., Medina-Santillan R., Villa A.R., Sanchez-Lara K., Ponciano-Rodriguez G., et al. The efficacy of adipokines and indices of metabolic syndrome as predictors of severe obesity-related hepatic steatosis. Dig. Dis. Sci. 51 (2006) 1716-1722
51. Nobili V., Manco M., Ciampalini P., Diciommo V., Devito R., Piemonte F., et al. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur. J. Endocrinol. 155 735 (2006) 743
52. Inoue M., Yano M., Yamakado M., Maehata E., and Suzuki S. Relationship between the adiponectin-leptin ratio and parameters of insulin resistance in subjects without hyperglycemia. Metabolism 55 (2006) 124-1254
53. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334 (1996) 292-295
54. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86 (2001) 1930-1935
55. Abbasi F., Chu J.W., Lamendola C., McLaufhlin T., Hayden J., Reaven G.M., et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes 53 (2004) 585-590
56. Lindsay R.S., Funahashi T., Hanson R.I., Matsuzawa Y., Tanaka S., Tataranni P.A., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
57. Spranger J., Kroke A., Mohlig M., Bergmann M.M., Ristow M., Boeing H., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361 (2003) 226-228
58. Vozarova B., Stefan N., Lindsay R.S., Krakoff J., Knowler W.C., Funahashi T., et al. Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes 51 (2002) 2964-2967
59. Bajaj M., Suraamornkul S., Piper P., Hardie L.J., Glass L., Cersosimo E., et al. Decreased plasma adiponectin concentration are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetes patients. J. Clin. Endocrinol. Metab. 89 (2004) 200-206
60. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342 (2000) 836-843
61. Koenig W., Sund M., Frohlich M., Fisher H.G., Lowel H., Doring A., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
62. Rutter M.K., Meigs J.B., Sullivan L.M., D'Agostino R.B., and Wilson P.W. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110 (2004) 380-385